Somatostatin Lyomark may be available in the countries listed below.
Somatostatin is reported as an ingredient of Somatostatin Lyomark in the following countries:
Somatostatin x acetate (a derivative of Somatostatin) is reported as an ingredient of Somatostatin Lyomark in the following countries:
International Drug Name Search
Generic Name: budesonide and formoterol inhalation (bue DES oh nide and for MOE te rol)
Brand names: Symbicort, Symbicort Turbuhaler, Symbicort 400/12 Turbohaler
Budesonide is a steroid that reduces inflammation in the body.
Formoterol is a bronchodilator that relaxes muscles in the airways to improve breathing.
The combination of budesonide and formoterol is used to prevent bronchospasm in people with asthma or chronic obstructive pulmonary disease (COPD).
Budesonide and formoterol inhalation may also be used for purposes not listed in this medication guide.
Use all of your medications as directed by your doctor. Talk with your doctor if your medications do not seem to work as well in treating or preventing attacks. Do not change your doses or medication schedule without advice from your doctor.
Before using budesonide and formoterol, tell your doctor if you have heart disease, high blood pressure, a seizure disorder, an infection (including herpes infection of the eyes), diabetes, tuberculosis, a thyroid disorder, or an electrolyte imbalance (such as low potassium levels in your blood).
To make sure you can safely use budesonide and formoterol, tell your doctor if you have any of these other conditions:
heart disease or high blood pressure;
epilepsy or other seizure disorder;
diabetes;
herpes infection of the eyes;
tuberculosis;
any active infection;
an electrolyte imbalance (such as low potassium levels in your blood); or
a thyroid disorder.
Long-term use of steroids may lead to bone loss (osteoporosis), especially if you smoke, if you do not exercise, if you do not get enough vitamin D or calcium in your diet, or if you have a family history of osteoporosis.
Budesonide and formoterol comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions. Always rinse your mouth after using the inhaler device.
Prime the inhaler device before the first use by pumping 2 test sprays into the air, away from your face. Shake the inhaler for at least 5 seconds before each spray. Prime the inhaler if it has not been used for longer than 7 days, or if the inhaler has been dropped.
Do not try to clean or take apart the inhaler device. Throw it away when the medicine runs out. Do not float the medicine canister in water. The dose indicator on the inhaler will turn red when there are 10 doses left in the device. Get your prescription refilled before you run out of medicine completely. Always use the new device provided with the medication when you get your prescription filled.
It may take up to 2 weeks before your symptoms improve. Keep using the medication as directed. Call your doctor if your symptoms do not improve after the first week of treatment, or if your symptoms get worse.
Your doctor will need to check your progress on a regular basis. Do not miss any scheduled appointments.
Your dosage needs may change if you have surgery, are ill, are under stress, or have recently had an asthma attack. Do not change your doses or medication schedule without advice from your doctor.
If you also use a steroid medication, do not stop using the steroid suddenly or you may have unpleasant withdrawal symptoms. Talk with your doctor about using less and less of the steroid before stopping completely.
Use all of your medications as directed by your doctor. Talk with your doctor if your medications do not seem to work as well in treating or preventing attacks. Do not change your doses or medication schedule without advice from your doctor.
Use the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
Overdose can cause redness around your nose, runny nose, trouble breathing, nervousness, muscle cramps, dry mouth, nausea, vomiting, sleep problems (insomnia), tremors, chest pain, fast or pounding heartbeats, fainting, and seizure (convulsions).
Using a steroid can lower the blood cells that help your body fight infections. Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medicines.
worsening asthma symptoms;
chest pain, fast or pounding heartbeats, tremors, nervousness;
wheezing, throat irritation, choking, or other breathing problems after using this medication;
signs of infection such as fever, chills, sore throat, flu symptoms, easy bruising or bleeding, unusual weakness;
blurred vision, eye pain, or seeing halos around lights;
white patches or sores in your mouth or throat; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects may include:
headache;
nausea, vomiting, diarrhea, upset stomach;
back pain;
stuffy nose;
muscle or joint pain; or
changes in your voice.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Asthma -- Maintenance:
For patients not currently on an inhaled corticosteroid, including patients on noncorticosteroid maintenance therapy, the recommended dosage is 2 inhalations of 80 mcg-4.5 mcg twice a day. Depending upon asthma severity, the dosage may be increased to 2 inhalations of 160 mcg-4.5 mcg twice a day.
For patients currently receiving medium to high doses of inhaled corticosteroid therapy, the recommended starting dose is 2 inhalations of 160 mcg-4.5 mcg twice a day.
For patients currently receiving low to medium to high doses of inhaled corticosteroid therapy, the recommended starting dose is 2 inhalations of 80 mcg-4.5 mcg twice a day.
Usual Adult Dose for Chronic Obstructive Pulmonary Disease -- Maintenance:
For maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema:
2 inhalations of budesonide-formoterol 160 mcg-4.5 mcg/inh by inhalation twice daily. Note: budesonide-formoterol 160 mcg-4.5 mcg/inh is the only approved dosage for the treatment of COPD.
Usual Pediatric Dose for Asthma -- Maintenance:
12 years or older:
For patients not currently on an inhaled corticosteroid, including patients on noncorticosteroid maintenance therapy, the recommended dosage is 2 inhalations of 80 mcg-4.5 mcg twice a day. Depending upon asthma severity, the dosage may be increased to 2 inhalations of 160 mcg-4.5 mcg twice a day.
For patients currently receiving medium to high doses of inhaled corticosteroid therapy, the recommended starting dose is 2 inhalations of 160 mcg-4.5 mcg twice a day.
For patients currently receiving low to medium to high doses of inhaled corticosteroid therapy, the recommended starting dose is 2 inhalations of 80 mcg-4.5 mcg twice a day.
Tell your doctor about all other medicines you use, especially:
antibiotics such as azithromycin (Zithromax), clarithromycin (Biaxin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), or telithromycin (Ketek);
antifungal medication such as ketoconazole (Nizoral), or itraconazole (Sporanox);
a diuretic (water pill);
an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate);
an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), doxepin (Sinequan, Silenor), nortriptyline (Pamelor), and others; or
a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others.
This list is not complete and other drugs may interact with budesonide and formoterol inhalation. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: budesonide and formoterol side effects (in more detail)
Omapro may be available in the countries listed below.
Omeprazole is reported as an ingredient of Omapro in the following countries:
International Drug Name Search
Medroxoral may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of Medroxoral in the following countries:
International Drug Name Search
Decreasing the size of the pupil after certain eye examinations or surgery.
Rev-Eyes is an antimydriatic. It works by blocking the smooth muscle contraction of the iris, which helps to decrease the size of the pupil.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Rev-Eyes. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Rev-Eyes. However, no specific interactions with Rev-Eyes are known at this time.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Rev-Eyes may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Rev-Eyes as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Rev-Eyes.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Headache; light sensitivity; redness and itching of the eyelids; redness or burning when you first put the medicine in your eye.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); swelling of the eyelid.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Rev-Eyes side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store mixed medicine at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), for 21 days. If Rev-Eyes is cloudy or discolored, discard it. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Rev-Eyes out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Rev-Eyes. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Claritron may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Claritron in the following countries:
International Drug Name Search
In the US, Clomid (clomiphene systemic) is a member of the drug class synthetic ovulation stimulants and is used to treat Female Infertility, Lactation Suppression, Oligospermia and Ovulation Induction.
US matches:
UK matches:
Clomifene citrate (a derivative of Clomifene) is reported as an ingredient of Clomid in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Riopan Gel may be available in the countries listed below.
Magaldrate is reported as an ingredient of Riopan Gel in the following countries:
International Drug Name Search
Lullan may be available in the countries listed below.
Perospirone hydrochloride (a derivative of Perospirone) is reported as an ingredient of Lullan in the following countries:
International Drug Name Search
Novanox may be available in the countries listed below.
Nitrazepam is reported as an ingredient of Novanox in the following countries:
International Drug Name Search
Noracin may be available in the countries listed below.
Norfloxacin is reported as an ingredient of Noracin in the following countries:
International Drug Name Search
Desossicortone may be available in the countries listed below.
Desossicortone (DCIT) is also known as Desoxycortone (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Emericid may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfadimethoxine is reported as an ingredient of Emericid in the following countries:
International Drug Name Search
Generic Name: neomycin, polymyxin B, and dexamethasone ophthalmic (NEE oh MYE sin, POL ee MIX in DEX a METH a sone off THAL mik)
Brand Names: Maxitrol, Ocu-Trol, Poly-Dex
Neomycin and polymyxin B are antibiotics. They are used to treat bacterial infections.
Dexamethasone is a steroid. It is used to treat the swelling associated with bacterial infections of the eye.
Neomycin, polymyxin B and dexamethasone ophthalmic may also be used for purposes other than those listed in this medication guide.
Contact your doctor if your symptoms begin to get worse or if you do not see any improvement in your condition after a few days.
Apply light pressure to the inside corner of your eye (near your nose) after each drop to prevent the fluid from draining down your tear duct.
Use neomycin, polymyxin B and dexamethasone eyedrops or ointment exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
To apply the eyedrops:
Shake the drops gently to be sure the medicine is well mixed. Tilt your head back slightly and pull down on your lower eyelid. Position the dropper above your eye. Look up and away from the dropper. Squeeze out a drop and close your eye. Apply gentle pressure to the inside corner of your eye (near your nose) for about 1 minute to prevent the liquid from draining down your tear duct. If you are using more than one drop in the same eye or drops in both eyes, repeat the process with about 5 minutes between drops.
To apply the ointment:
Hold the tube in your hand for a few minutes to warm it up so that the ointment comes out easily. Tilt your head back slightly and pull down gently on your lower eyelid. Apply a thin film of the ointment into your lower eyelid. Close your eye and roll your eyeball around in all directions for 1 to 2 minutes. If you are applying another eye medication, allow at least 10 minutes before your next application.
Never use any eyedrop that is discolored or has particles in it.
Apply the missed dose as soon as you remember. However, if it is almost time for your next regularly scheduled dose, skip the missed dose and apply the next one as directed. Do not use a double dose of this medication.
An overdose of this medication is unlikely to occur. If you do suspect an overdose, wash the eye with water and call an emergency room or poison control center near you. If the drops or ointment have been ingested, drink plenty of fluid and call an emergency center for advice.
Use caution with contact lenses. Wear them only if your doctor approves. After applying this medication, wait at least 15 minutes before inserting contact lenses.
Avoid other eye medications unless your doctor approves.
Serious side effects are not expected with this medication.
Some burning, stinging, irritation, itching, redness, blurred vision, eyelid itching, eyelid swelling, or sensitivity to light may occur.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Avoid other eye medications unless they are approved by your doctor.
Before using this medication, tell your doctor if you are taking an oral steroid medication such as prednisone (Deltasone, Orasone, others).
Drugs other than those listed here may also interact with neomycin, polymyxin B and dexamethasone ophthalmic. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
See also: Dexacidin side effects (in more detail)
Hi Tet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxytetracycline dihydrate (a derivative of Oxytetracycline) is reported as an ingredient of Hi Tet in the following countries:
Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Hi Tet in the following countries:
International Drug Name Search
Rx only
FOR EXTERNAL USE ONLY. FOR DERMATOLOGIC USE ONLY.
NOT FOR OPHTHALMIC USE.
Desonide Cream 0.05% and Ointment 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β, 16α)) a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Chemically, desonide is C24H32O6. It has the following structural formula:
Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water.
Each gram of Desonide Cream contains 0.5 mg of desonide in a compatible vehicle buffered to the pH range of normal skin. It contains aluminum acetate basic, cetearyl alcohol/SLS/SCS, glycerin, mineral oil, purified water, white petrolatum and white wax. It is preserved with methylparaben.
Each gram of Desonide Ointment contains 0.5 mg of desonide in an ointment base consisting of mineral oil and white petrolatum.
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Studies performed with Desonide Cream and ointment indicate that they are in the low to medium range of potency as compared with other topical corticosteroids.
Desonide Cream and ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Desonide Cream and ointment are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS - Pediatric Use)
If irritation develops, Desonide Cream or ointment should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Desonide Cream or ointment should be discontinued until the infection has been adequately controlled.
Patients using topical corticosteroids should receive the following information and instructions:
The following tests may be helpful in evaluating patients for HPA axis suppression:
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on reproduction with the use of Desonide Cream or ointment.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproduction studies have not been conducted with Desonide Cream or ointment. It is also not known whether Desonide Cream or ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Desonide Cream and ointment should be given to a pregnant woman only if clearly needed.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desonide Cream or ointment is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning, approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.
The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Topically applied Desonide Cream and ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS)
Desonide Cream or ointment should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Desonide Cream and ointment should not be used with occlusive dressings.
Desonide Cream 0.05% is supplied in 60 g (NDC 23589-052-60) tubes.
Desonide Ointment 0.05% is supplied in 60 g (NDC 23589-053-60) tubes.
Store at 20°- 25°C (68°- 77°F). [see USP Controlled Room Temperature].
Protect from freezing.
Manufactured by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1
Manufactured for: TIBER LABORATORIES, Suwanee, GA 30024
Issued: April, 2010
REV. 04/10 052/053-10
PK-6513-0
95
NDC 23589-052-60
Desonide
Cream 0.05%
FOR EXTERNAL USE ONLY.
NOT FOR OPHTHALMIC USE.
Keep this and all medications out of the reach of children.
TIBER
LABORATORIES
60 g
Rx only
| DESONIDE desonide cream | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA073548 | 06/30/1992 | 06/30/2012 |
| Labeler - Tiber Laboratories, LLC (008913939) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Taro Pharmaceuticals Inc. | 206263295 | MANUFACTURE | |
In some countries, this medicine may only be approved for veterinary use.
BAN
P03BA02
0052315-07-8
C22-H19-Cl2-N-O3
416
Insecticide
Pediculocide
Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, cyano(3-phenoxyphenyl)methyl ester
International Drug Name Search
Glossary
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| OS | Official Synonym |
Apo-Pyridoxine may be available in the countries listed below.
Pyridoxine hydrochloride (a derivative of Pyridoxine) is reported as an ingredient of Apo-Pyridoxine in the following countries:
International Drug Name Search
Isquelium may be available in the countries listed below.
Acenocoumarol is reported as an ingredient of Isquelium in the following countries:
International Drug Name Search
Dobutel may be available in the countries listed below.
Dobutamine hydrochloride (a derivative of Dobutamine) is reported as an ingredient of Dobutel in the following countries:
International Drug Name Search
Gliciron may be available in the countries listed below.
Glibenclamide is reported as an ingredient of Gliciron in the following countries:
International Drug Name Search
Miovisin may be available in the countries listed below.
Acetylcholine Chloride is reported as an ingredient of Miovisin in the following countries:
International Drug Name Search
Alprocontin may be available in the countries listed below.
Alprazolam is reported as an ingredient of Alprocontin in the following countries:
International Drug Name Search
Apurin-Hexal may be available in the countries listed below.
Allopurinol is reported as an ingredient of Apurin-Hexal in the following countries:
International Drug Name Search
Cefatron Asciutta may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cefapirin benzathine (a derivative of Cefapirin) is reported as an ingredient of Cefatron Asciutta in the following countries:
International Drug Name Search
Irinotecan Zyo may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotecan Zyo in the following countries:
International Drug Name Search
Lafarin may be available in the countries listed below.
Cefalexin is reported as an ingredient of Lafarin in the following countries:
International Drug Name Search
In the US, Sal-Tropine (atropine systemic) is a member of the following drug classes: anticholinergic chronotropic agents, anticholinergics/antispasmodics, antidotes and is used to treat Anticholinesterase Poisoning, AV Heart Block and Bradyarrhythmia.
US matches:
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Sal-Tropine in the following countries:
International Drug Name Search
Briklin may be available in the countries listed below.
Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Briklin in the following countries:
International Drug Name Search
Fanil may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Fanil in the following countries:
International Drug Name Search
Eposino may be available in the countries listed below.
Epoetin Alfa is reported as an ingredient of Eposino in the following countries:
International Drug Name Search
Morphin Hexal may be available in the countries listed below.
Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of Morphin Hexal in the following countries:
International Drug Name Search
Diaglin may be available in the countries listed below.
Glimepiride is reported as an ingredient of Diaglin in the following countries:
International Drug Name Search
Bivacyn may be available in the countries listed below.
Bacitracin is reported as an ingredient of Bivacyn in the following countries:
Neomycin is reported as an ingredient of Bivacyn in the following countries:
International Drug Name Search
Alphazol may be available in the countries listed below.
Alfacalcidol is reported as an ingredient of Alphazol in the following countries:
International Drug Name Search
Moniten may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Moniten in the following countries:
International Drug Name Search
CO Risperidone may be available in the countries listed below.
Risperidone is reported as an ingredient of CO Risperidone in the following countries:
International Drug Name Search
Euglucon 5 may be available in the countries listed below.
Glibenclamide is reported as an ingredient of Euglucon 5 in the following countries:
International Drug Name Search
Urequin may be available in the countries listed below.
Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Urequin in the following countries:
International Drug Name Search
Spirasol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Spiramycin embonate (a derivative of Spiramycin) is reported as an ingredient of Spirasol in the following countries:
International Drug Name Search
In the US, Viread (tenofovir systemic) is a member of the drug class nucleoside reverse transcriptase inhibitors (NRTIs) and is used to treat Hepatitis B, HIV Infection and Nonoccupational Exposure.
US matches:
UK matches:
Tenofovir is reported as an ingredient of Viread in the following countries:
Tenofovir disoproxil fumarate (a derivative of Tenofovir) is reported as an ingredient of Viread in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Algophene may be available in the countries listed below.
Dextropropoxyphene hydrochloride (a derivative of Dextropropoxyphene) is reported as an ingredient of Algophene in the following countries:
International Drug Name Search
Nimesulide Sandoz may be available in the countries listed below.
Nimesulide is reported as an ingredient of Nimesulide Sandoz in the following countries:
International Drug Name Search
Doloxene may be available in the countries listed below.
Dextropropoxyphene napsilate (a derivative of Dextropropoxyphene) is reported as an ingredient of Doloxene in the following countries:
Ibuprofen is reported as an ingredient of Doloxene in the following countries:
International Drug Name Search
In the US, Ulipristal (ulipristal systemic) is a member of the drug class progesterone receptor modulators and is used to treat Birth Control and Emergency Contraception.
US matches:
Rec.INN
0159811-51-5
C28-H35-N-O3
433
Emergency contraceptive, selective progesterone receptor modulator, SPRM
11beta-[4-(dimethylamino)phenyl]-17-hydroxy-19-norpregna-4,9-diene-3,20-dione (WHO)
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Ceftazidima EG may be available in the countries listed below.
Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Ceftazidima EG in the following countries:
International Drug Name Search
Generic Name: propoxyphene (pro POX i feen)
Brand Names: Darvon, Darvon-N
Propoxyphene was withdrawn from the U.S. market in November 2010.
Propoxyphene is in a group of drugs called narcotic pain relievers.
Propoxyphene is used to relieve mild to moderate pain.
Propoxyphene may also be used for other purposes not listed in this medication guide.
Propoxyphene was withdrawn from the U.S. market in November 2010.
If you have any of these other conditions, you may need a dose adjustment or special tests:
asthma, COPD, sleep apnea, or other breathing disorders;
a history of head injury or brain tumor;
mental illness; or
a history of drug or alcohol addiction.
Older adults may be more sensitive to the effects of this medicine.
Take this medication exactly as it was prescribed for you. Never take propoxyphene in larger amounts, or use it for longer than recommended by your doctor. Follow the directions on your prescription label. Tell your doctor if the medicine seems to stop working as well in relieving your pain.
Since propoxyphene is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
Overdose symptoms may include extreme drowsiness, pinpoint or dilated pupils, confusion, cold and clammy skin, blue lips, weak pulse, slow or uneven heart rate, shallow breathing, fainting, or breathing that stops.
Grapefruit and grapefruit juice may interact with propoxyphene and lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.
shallow breathing, slow heartbeat;
feeling light-headed, fainting;
confusion, hallucinations, unusual thoughts or behavior;
seizure (convulsions); or
jaundice (yellowing of the skin or eyes).
Less serious side effects include:
feeling dizzy or drowsy;
nausea, vomiting, stomach pain, constipation;
headache, muscle pain;
blurred vision; or
mild skin rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medicines you use, especially:
amiodarone (Cordarone, Pacerone);
aprepitant (Emend);
bosentan (Tracleer);
conivaptan (Vaprisol);
dexamethasone (Decadron, Hexadrol);
imatinib (Gleevec);
isoniazid (for treating tuberculosis);
St. John's wort;
an antibiotic such as clarithromycin (Biaxin), dalfopristin/quinupristin (Synercid), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), rifampin (Rifadin, Rifater, Rifamate), or telithromycin (Ketek);
antifungal medication such as clotrimazole (Mycelex Troche), fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral), or voriconazole (Vfend);
an antidepressant such as nefazodone;
a barbiturate such as butabarbital (Butisol), secobarbital (Seconal), pentobarbital (Nembutal), or phenobarbital (Solfoton);
a blood thinner such as warfarin (Coumadin);
heart or blood pressure medication such as diltiazem (Cartia, Cardizem), felodipine (Plendil), nifedipine (Nifedical, Procardia), verapamil (Calan, Covera, Isoptin, Verelan), and others;
HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), efavirenz (Sustiva), etravirine (Intelence), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), saquinavir (Invirase), or ritonavir (Norvir);
medicines to treat narcolepsy, such as armodafanil (Nuvigil) or modafanil (Progivil); or
seizure medication such as carbamazepine (Carbatrol, Tegretol), felbamate (Felbatol), oxcarbazepine (Trileptal), or phenytoin (Dilantin), or primidone (Mysoline).
This list is not complete and other drugs may interact with propoxyphene. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Darvon-N side effects (in more detail)
